Agnieszka Kuczaj1, Ewa Nowalany-Kozielska2, Michał Skrzypek3, Grzegorz Opolski4, Aneta Ociessa5, Ewa Jankowska6, Piotr Ponikowski6, Beata Wożakowska-Kapłon7, Ewa Mirek-Brynarska8, Jarosław Drożdż9. 1. 2nd Department of Cardiology, School of Medicine with the Division of Dentistry in Zabrze, SUM, Zabrze, Poland. agnieszka.kuczaj@gmail.com. 2. 2nd Department of Cardiology, School of Medicine with the Division of Dentistry in Zabrze, SUM, Zabrze, Poland. 3. Department of Biostatistics, School of Public Health in Bytom, SUM, Bytom, Poland. 4. 1 Department of Cardiology and Cardiosurgery, Medical University of Warsaw, Warsaw, Poland. 5. 3rd Department of Cardiology, Silesian Centre for Heart Diseases, Medical University of Silesia, Zabrze, Poland. 6. Department of Heart Diseases, Wroclaw Medical University, Centre for Heart Diseases, Military Hospital, Wroclaw, Poland. 7. 1st Department of Cardiology and Electrotherapy, Swietokrzyskie Centre of Cardiology, University of Jan Kochanowski, Kielce, Poland. 8. Department of Cardiology, Dietl Specialistic Hospital, Krakow, Poland. 9. Department of Cardiology, Medical University of Lodz, Lodz, Poland.
Abstract
BACKGROUND: Heart failure (HF) has become an epidemic. A similar situation is also observed for atrial fibrillation (AF). The CHA2DS2-VASc score is one of the most useful tools for thromboembolic risk assessment. AIM: The aim of the study was to assess the prevalence of AF in patients with decompensated HF, who were divided into subgroups according to the CHA2DS2-VASc score. METHODS: We analysed the prevalence of AF in a group of 1108 patients (327 women) hospitalised due to HF decompensa- tion in medical centres of different referral levels. Twenty-one patients refused to participate in the registry. The data were collected from Polish centres included in the European Society of Cardiology Heart Failure Long-Term Registry. The recruit- ment period was from 2011 to 2014. The data were analysed retrospectively. Patients were divided into groups according to the CHA2DS2-VASC score. RESULTS: The study sample was characterised by a high occurrence of AF (44.3%), with the highest prevalence in patients with a CHA2DS2-VASC score ≥ 6 (61.3%, p = 0.01). CONCLUSIONS: The CHA2DS2-VASc score may be a useful tool for detecting patients with HF characterised by the highest risk of AF.
BACKGROUND:Heart failure (HF) has become an epidemic. A similar situation is also observed for atrial fibrillation (AF). The CHA2DS2-VASc score is one of the most useful tools for thromboembolic risk assessment. AIM: The aim of the study was to assess the prevalence of AF in patients with decompensated HF, who were divided into subgroups according to the CHA2DS2-VASc score. METHODS: We analysed the prevalence of AF in a group of 1108 patients (327 women) hospitalised due to HF decompensa- tion in medical centres of different referral levels. Twenty-one patients refused to participate in the registry. The data were collected from Polish centres included in the European Society of Cardiology Heart Failure Long-Term Registry. The recruit- ment period was from 2011 to 2014. The data were analysed retrospectively. Patients were divided into groups according to the CHA2DS2-VASC score. RESULTS: The study sample was characterised by a high occurrence of AF (44.3%), with the highest prevalence in patients with a CHA2DS2-VASC score ≥ 6 (61.3%, p = 0.01). CONCLUSIONS: The CHA2DS2-VASc score may be a useful tool for detecting patients with HF characterised by the highest risk of AF.